2023 World Conference on Lung Cancer (Posters)-P1.13. Targeting SGLT2 for Early Diagnosis of Lung Adenocarcinoma

P1.13. Targeting SGLT2 for Early Diagnosis of Lung Adenocarcinoma - PDF(Abstract)

Pdf Summary

Lung cancer is a leading cause of cancer-related deaths, and early diagnosis is crucial for successful treatment. High-resolution computed tomography (CT) has improved early detection, but it has low specificity and can identify benign lesions. Researchers at UCLA have discovered that targeting the sodium-glucose transporter 2 (SGLT2) can be an effective method for early diagnosis of lung adenocarcinoma (LUAD). SGLT2 is present in premalignant and well-differentiated LUAD and is necessary for the metabolic activity of early-stage lesions. The researchers used a positron emission tomography (PET) tracer called methyl-4-[18F] fluorodeoxyglucose (Me4FDG) to measure SGLT2 activity in vivo. They conducted a pilot clinical trial with 10 patients and pre-clinical studies in mouse models and patient-derived organoids to confirm the specificity of Me4FDG. The results showed that Me4FDG can detect early-stage LUAD that is not detected by the standard PET tracer. Me4FDG was also able to image human ground glass nodules, which are often found incidentally or through screening but may be benign or LUAD. Based on these findings, the researchers plan to initiate a phase I/II clinical trial with Me4FDG in patients with screen-detected lung nodules. Overall, this research suggests that Me4FDG PET could be a valuable tool for the early detection of LUAD, allowing for more effective treatment options.

Asset Subtitle

Claudio Scafoglio

Meta Tag

Speaker Claudio Scafoglio

Topic Screening & Early Detection: Biomarkers/Imaging Technology

Keywords

Lung cancer

Early diagnosis

Computed tomography

SGLT2

Lung adenocarcinoma

PET tracer

Me4FDG

Metabolic activity

Clinical trial

Treatment options